Company Filing History:
Years Active: 2016-2025
Title: Innovations by Marcus Järås in Cancer Treatment
Introduction
Marcus Järås is a prominent inventor based in Lund, Sweden, known for his significant contributions to the field of cancer treatment. With a total of 13 patents to his name, Järås has focused on developing innovative methods to combat IL1RAP associated cancers. His work is pivotal in advancing therapeutic options for patients suffering from various forms of cancer.
Latest Patents
Among his latest patents, Järås has developed methods for treating IL1RAP associated cancers using anti-human interleukin-1 receptor accessory protein (IL1RAP) antibodies. This invention provides an antibody or an antigen-binding fragment that specifically binds to human IL1RAP, effectively inhibiting the binding of the antibody 'CAN04' to this protein. Furthermore, he has created agents that utilize binding moieties with specificity for IL1RAP to induce cell death and inhibit the growth of cells associated with solid tumors. These agents are also designed for detecting pathological cells linked to solid tumors, showcasing their dual utility in both treatment and diagnosis.
Career Highlights
Järås is currently associated with Cantargia AB, a company dedicated to developing innovative cancer therapies. His work at Cantargia has been instrumental in pushing the boundaries of cancer research and treatment methodologies. His patents reflect a deep understanding of the molecular mechanisms involved in cancer progression and the potential for targeted therapies.
Collaborations
Some of his notable coworkers include Thoas Fioretos and Helena Ågerstam, who have collaborated with him on various projects aimed at enhancing cancer treatment strategies. Their combined expertise contributes to the innovative environment at Cantargia AB.
Conclusion
Marcus Järås stands out as a key figure in the field of cancer research, with his patents paving the way for new therapeutic approaches. His dedication to innovation continues to inspire advancements in the treatment of IL1RAP associated cancers.